Evidence map›Paper›PMID 29338042›Full record

ArticlePloS one2018

A pharmacological screen for compounds that rescue the developmental lethality of a Drosophila ATM mutant.

Stacey A Rimkus, David A Wassarman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Modeling Neurodegenerative Disorders inInternational journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Stacey A RimkusDepartment of Medical Genetics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
David A WassarmanDepartment of Medical Genetics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.ORCID 0000-0002-7042-9561
University of Wisconsin–Madison · US

Funding

Genetic Analysis of Neurodegeneration in DrosophilaR01NS083596 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI WASSARMAN, DAVID · 2014 to 2018
$1.6M
Neuroprotective drugs for A-TR21NS085302 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI WASSARMAN, DAVID · 2013 to 2014
$404k
NINDS NIH HHS R01 NS083596NINDS NIH HHS R21 NS085302
6 · The paper itself

Abstract

Ataxia-telangiectasia (A-T) is a neurodegenerative disease caused by mutation of the A-T mutated (ATM) gene. ATM encodes a protein kinase that is activated by DNA damage and phosphorylates many proteins, including those involved in DNA repair, cell cycle control, and apoptosis. Characteristic biological and molecular functions of ATM observed in mammals are conserved in Drosophila melanogaster. As an example, conditional loss-of-function ATM alleles in flies cause progressive neurodegeneration through activation of the innate immune response. However, unlike in mammals, null alleles of ATM in flies cause lethality during development. With the goals of understanding biological and molecular roles of ATM in a whole animal and identifying candidate therapeutics for A-T, we performed a screen of 2400 compounds, including FDA-approved drugs, natural products, and bioactive compounds, for modifiers of the developmental lethality caused by a temperature-sensitive ATM allele (ATM8) that has reduced kinase activity at non-permissive temperatures. Ten compounds reproducibly suppressed the developmental lethality of ATM8 flies, including Ronnel, which is an organophosphate. Ronnel and other suppressor compounds are known to cause mitochondrial dysfunction or to inhibit the enzyme acetylcholinesterase, which controls the levels of the neurotransmitter acetylcholine, suggesting that detrimental consequences of reduced ATM kinase activity can be rescued by inhibiting the function of mitochondria or increasing acetylcholine levels. We carried out further studies of Ronnel because, unlike the other compounds that suppressed the developmental lethality of homozygous ATM8 flies, Ronnel was toxic to the development of heterozygous ATM8 flies. Ronnel did not affect the innate immune response of ATM8 flies, and it further increased the already high levels of DNA damage in brains of ATM8 flies, but its effects were not harmful to the lifespan of rescued ATM8 flies. These results provide new leads for understanding the biological and molecular roles of ATM and for the treatment of A-T.

Indexed as

AllelesAnimalsAtaxia Telangiectasia Mutated ProteinsDNA DamageDrosophila melanogasterDrosophila ProteinsDrug Evaluation, PreclinicalFemaleGenes, InsectGenes, LethalImmunity, InnateMaleMutationNerve DegenerationOrganothiophosphorus CompoundsPhenotypeAtaxia Telangiectasia Mutated ProteinsDrosophila ProteinsOrganothiophosphorus CompoundsProtein Serine-Threonine KinasesronnelTefu protein, Drosophila

Identifiers

PMID29338042
PMCPMC5770031
OpenAlexW2783286861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.